VIRAMUNE Drug Patent Profile

When do Viramune patents expire, and when can generic versions of Viramune launch?

Viramune is a drug marketed by Boehringer Ingelheim and is included in three NDAs. There is one patent protecting this drug.

The generic ingredient in VIRAMUNE is nevirapine. There are twenty drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the nevirapine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viramune

A generic version of VIRAMUNE was approved as nevirapine by AUROBINDO on May 22^nd, 2012.

Summary for VIRAMUNE

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	121
Clinical Trials:	42
Patent Applications:	5,703
Drug Prices:	Drug price information for VIRAMUNE
What excipients (inactive ingredients) are in VIRAMUNE?	VIRAMUNE excipients list
DailyMed Link:	VIRAMUNE at DailyMed

See drug prices for VIRAMUNE

Recent Clinical Trials for VIRAMUNE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institutes of Health (NIH)	Phase 4
Columbia University	Phase 4
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 4

See all VIRAMUNE clinical trials

US Patents and Regulatory Information for VIRAMUNE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	VIRAMUNE	nevirapine	SUSPENSION;ORAL	020933-001	Sep 11, 1998		DISCN	Yes	No
Boehringer Ingelheim	VIRAMUNE XR	nevirapine	TABLET, EXTENDED RELEASE;ORAL	201152-001	Mar 25, 2011		DISCN	Yes	No
Boehringer Ingelheim	VIRAMUNE	nevirapine	TABLET;ORAL	020636-001	Jun 21, 1996		DISCN	Yes	No
Boehringer Ingelheim	VIRAMUNE XR	nevirapine	TABLET, EXTENDED RELEASE;ORAL	201152-002	Nov 8, 2012		DISCN	Yes	No

EU/EMA Drug Approvals for VIRAMUNE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Viramune	nevirapine	EMEA/H/C/000183Tablets and oral suspensionViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults, adolescents, and children of any age.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.50- and 100-mg prolonged-release tabletsViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adolescents and children three years and above and able to swallow tablets.Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.400-mg prolonged-release tabletsViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults, adolescents and children three years and above and able to swallow tablets.Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.	Authorised	no	no	no	1998-02-04
Teva B.V.	Nevirapine Teva	nevirapine	EMEA/H/C/001119Nevirapine Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV 1 infected adults, adolescents, and children of any age.Most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing.	Withdrawn	yes	no	no	2009-11-30

International Patents for VIRAMUNE

See the table below for patents covering VIRAMUNE around the world.

Country	Patent Number	Title	Estimated Expiration
Greece	3030100
Japan	H0363276	NOVEL 5,11-DIHYDRO-6H-DIPYRIDO(3,2-B:2',3'-E) (1,4) DIAZEPINE-6-ONE AND PHARMACEUTICAL COMPO- SITION CONTAINING COMPOUND THEREOF FOR PREVENTING AND TREATING AIDS
Canada	2014771	5,11-DIHYDRO-6H-DIPYRIDO[3,2-B:2'3'-E][1,4]DIAZEPINE-6-ONES ET LEUR UTILISATION POUR LA PREVENTION OU LE TRAITEMENT DU SIDA (5,11-DIHYDRO-6H-DIPYRIDO[3,2-B:2'3'-E][1,4]DIAZEPIN-6-ONES AND THEIR USE IN THE PREVENTION OR TREATMENT OF AIDS)
Germany	69007891

Supplementary Protection Certificates for VIRAMUNE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0429987	9990018-5 9991018-4	Sweden		PRODUCT NAME: 5,11-DIHYDRO-6H-DIPYRIDO3,2-B:2,3-E1,4DIAZEPINER OCH DERAS ANVAENDNING VID PREVENTION ELLER BEHANDLING AV HIV-INFEKTION; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRTION: LI 54393 19971223
0429987	990022	Netherlands		990022, 20101116, EXPIRES: 20121222
0429987	C990022	Netherlands		PRODUCT NAME: NEVIRAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION: CH 54393 19971223
0429987	99C0021	Belgium		PRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION NO/DATE: CH 54393 19971223

Market Dynamics and Financial Trajectory for VIRAMUNE (Nevirapine)

Last updated: January 23, 2026

Summary

VIRAMUNE (nevirapine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used primarily in antiretroviral therapy (ART) for HIV-1 infections. Introduced in the late 1990s, VIRAMUNE remains relevant despite the evolving HIV treatment landscape. This report analyzes current market dynamics, sales trends, competitive positioning, regulatory considerations, and forecasted financial trajectories. It synthesizes data from industry reports, regulatory filings, and market analyses to provide a comprehensive view tailored for stakeholders in pharmaceutical investment, development, and strategic planning.

---

What Are the Current Market Dynamics for VIRAMUNE?

Market Position and Usage Trends

Factor	Details
Market Penetration	VIRAMUNE holds a significant share in low- and middle-income countries (LMICs) due to its affordability and WHO recommendations. It is less dominant in high-income countries, replaced increasingly by integrase inhibitors (e.g., dolutegravir) owing to superior efficacy and safety profiles.
Indication Scope	Approved for HIV-1 infection treatment, often as part of combination ART regimens. Its role is more prominent in resource-limited settings.
Prescription Trends	Declined in high-income markets due to evolving treatment guidelines favoring integrase strand transfer inhibitors (INSTIs). However, demand remains stable or slightly increasing in LMICs due to cost advantages and existing procurement deals.

Competitive Landscape

Player	Product(s)	Market Share (%)	Key Attributes
Viramune (Boehringer Ingelheim)	Nevirapine	~10-15% (global)	Established first-generation NNRTI, long-term safety data, low cost
Alternative NNRTIs	Efavirenz — replaced in many settings by drugs like Dolutegravir	~60% (by NNRTI class)	Better tolerability, higher barrier to resistance
Integrase Inhibitors	Dolutegravir, Bictegravir	Major (>50%) in high-income markets	Demonstrated superior safety and efficacy profiles

Regulatory and Policy Influences

Aspect	Impact
WHO Guidelines (2021)	Recommends replacing NNRTIs with shorter, more tolerable regimens, reducing VIRAMUNE's indications in high-income countries.
Patent Status	Patent expired in major markets (e.g., US in 2015), leading to generic competition, especially in LMICs.
Approved Formulations	Tablet and pediatric formulations. Licensing agreements influence market access in developing regions.

Supply Chain and Distribution Channels

• Global Procurement | Dominated by global health organizations (e.g., UNITAID, PEPFAR) for LMIC distribution.
• Pricing Strategies | Tiered pricing models and voluntary licensing agreements enable broad access, yet profit margins in high-income markets are limited due to generic competition.

---

What Is the Financial Trajectory for VIRAMUNE?

Sales Trends (Past and Current)

Year	Global Sales (USD billions)	Notes
2018	$0.1–0.2	Stable sales primarily from LMIC procurement contracts
2019	$0.15	Slight growth driven by generic uptake in Africa
2020	$0.2	Pandemic-related disruptions offset by continued demand in resource-limited regions
2021	~$0.25	Incremental growth, renewed procurement in some markets

Key Revenue Drivers

• Volume Growth | Steady demand in LMICs, driven by WHO and PEPFAR procurement.
• Pricing | Lower margins in LMICs; limited in high-income push due to preference for newer drugs.
• Licensing & Generics | Generics dominate, reducing per-unit revenue but increasing sales volume.

Future Revenue Forecasts

Year	Estimated Sales (USD millions)	Assumptions	Source/Methodology
2025	$250–$300	Continued demand in LMICs, no major patent interventions	Market trend extrapolations, WHO policy shifts
2030	$200–$250	Possible decline in LMICs due to newer regimens; stabilization	Market penetration assessments, treatment guideline evolution

Factors Affecting Financial Outlook

Factor	Impact
Market Shift to INSTIs	Decreases in demand for NNRTI-based regimens
Generic Competition	Pressures on pricing, margins
Global HIV Treatment Goals	Increased access in LMICs sustains volume, though at lower margins
Pipeline Innovations	Development of fixed-dose combinations including VIRAMUNE ingredients may extend lifecycle

---

How Do Regulatory Policies and Global Initiatives Influence the Market?

• WHO and Global Fund Policies dictate regimen standardization favoring integrase inhibitors, potentially limiting VIRAMUNE's growth.
• Expanded Access Programs in Africa and Asia favor VIRAMUNE due to its affordability and established safety profile.
• Patent Expirations have facilitated the proliferation of generic versions, notably in India and Africa.

How Does the Competitive Environment Affect VIRAMUNE's Financial Trajectory?

Aspect	Effect
Price Competition	Generics and licensing lower prices, limiting revenue per unit.
Therapeutic Advances	Introduction of more tolerable and higher barrier drugs diminishes VIRAMUNE’s market share.
Market Reentry Opportunities	Potential niche in specific populations not suitable for newer drugs, e.g., pediatric cases.

---

What Are the Key Market Segments and Regional Dynamics?

Region	Dominant Treatment Trends	VIRAMUNE's Position	Growth Potential
Sub-Saharan Africa	Generic-based, WHO-guided	Major supplier via generics	Stable to modest growth
Asia (India, Southeast Asia)	Price-sensitive markets	Significant provider through licensing	Steady demand
Europe & North America	Prefer newer agents	Minimal; declining	Limited, unless in specific niches
Latin America	Mix of generics and branded	Moderate presence	Stable, potential for niche use

---

Comparison Table: VIRAMUNE Versus Contemporary HIV Drugs

Attribute	VIRAMUNE (Nevirapine)	Dolutegravir	Efavirenz	Cabotegravir
Approval Year	1996	2013	1998	2020
Formulations	Tablets, pediatric	Tablets, injectables	Tablets	Injectable
Efficacy	Moderate	High	Moderate	High
Safety Profile	Hematologic, hepatic risks	Better tolerability	Neuropsychiatric effects	Favorable
Cost (USD)	Very low (generic)	Moderate to high	Moderate	Varies

---

Key Policy and Market Entry Considerations

• Price Sensitivity: Viramune's low-cost profile sustains demand in resource-limited regions.
• Patent Landscape: Patent expiration in major markets enables generic competition, affecting revenue potential.
• Regulatory Approvals: Ongoing approvals or restrictions in key markets influence market sustainability.
• Programmatic Integration: Inclusion in global HIV treatment programs directly impacts sales volumes.

---

Key Takeaways

• Market Position: VIRAMUNE remains crucial in LMICs due to affordability and global health initiatives but faces declining relevance in high-income markets.
• Revenue Trajectory: Sales are projected to plateau or decline gradually by 2030, driven by increased adoption of integrase inhibitors.
• Competitive Dynamics: Generics and newer drug regimens exert downward pressure on prices and market share.
• Regulatory Impact: WHO guidelines and patent expirations favor market access but also accelerate the shift toward newer therapies.
• Strategic Opportunities: Focus on niche markets, pediatric formulations, and combination therapies may prolong product lifecycle.

---

Frequently Asked Questions (FAQs)

Q1: What is the expected lifespan of VIRAMUNE in the global HIV treatment landscape?
A1: While its core role is diminishing in high-income countries, VIRAMUNE’s lifespan extends through continued use in LMICs under global health initiatives—estimated into the late 2030s, depending on policy shifts and innovations.

Q2: How does the patent environment influence VIRAMUNE’s market?
A2: Patent expirations in major markets like the US (2015) and Europe have led to widespread generic production, lowering prices and profits. Ongoing patent protections or patents filings can temporarily restrict generic competition in specific jurisdictions.

Q3: Are there any opportunities for new formulations or delivery methods for VIRAMUNE?
A3: Fixed-dose combination tablets and pediatric formulations remain potential avenues to extend its market life, particularly aligning with global HIV treatment goals.

Q4: How do global HIV treatment policies impact VIRAMUNE's market?
A4: Guidelines favoring INSTIs and newer drugs limit VIRAMUNE’s use in high-income countries but sustain demand in resource-limited settings where cost is paramount.

Q5: What is the comparative advantage of VIRAMUNE over newer drugs?
A5: Its primary advantages are low cost, established safety profile, and widespread acceptance in resource-limited regions, despite inferior tolerability and efficacy compared to newer agents.

---

References

1. WHO HIV Treatment Guidelines, 2021.
2. Boehringer Ingelheim Annual Reports, 2018–2021.
3. Market research reports from IQVIA, 2022.
4. Patent and regulatory filings, 2022.
5. UNAIDS Global HIV Statistics, 2022.